SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr Reddy's eyes delisting of OctoPlus from bourses

01 Mar 2013 Evaluate

Dr Reddy's Laboratories, is getting ready to delist its Netherlands-based speciality pharma company - OctoPlus NV from Euronext as the Indian drug makers have acquired 98.6% of its shares. The entity will start the squeeze-out proceedings in order to acquire the remaining shares not tendered and not held by it or OctoPlus.

Indian drug major had announced the plan to acquire OctoPlus NV for about 27.4 million euros on October 22 last year. According to the agreement, the company made an open offer to purchase all outstanding shares of OctoPlus at an offer price of 0.52 euro in cash for each share.

 

Dr. Reddys Labs. Share Price

1382.70 32.70 (2.42%)
29-Jun-2026 14:38 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1872.60
Dr. Reddys Labs. 1382.70
Cipla 1459.35
Zydus Lifesciences 1115.70
Lupin 2379.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: